Omega-3 fatty acids, energy substrates, and brain function during aging.
The maintenance of optimal cognitive function is a central feature of healthy aging. Impairment in brain glucose uptake is common in aging associated cognitive deterioration, but little is known of how this problem arises or whether it can be corrected or bypassed. Several aspects of the challenge to providing the brain with an adequate supply of fuel during aging seem to relate to omega-3 fatty acids. For instance, low intake of omega-3 fatty acids, especially docosahexaenoic acid (DHA), is becoming increasingly associated with several forms of cognitive decline in the elderly, particularly Alzheimer's disease. Brain DHA level seems to be an important regulator of brain glucose uptake, possibly by affecting the activity of some but not all the glucose transporters. DHA synthesis from either alpha-linolenic acid (ALA) or eicosapentaenoic acid (EPA) is very low in humans begging the question of whether these DHA precursors are likely to be helpful in maintaining cognition during aging. We speculate that ALA and EPA may well have useful supporting roles in maintaining brain function during aging but not by their conversion to DHA. ALA is an efficient ketogenic fatty acid, while EPA promotes fatty acid oxidation. By helping to produce ketone bodies, the effects of ALA and EPA could well be useful in strategies intended to use ketones to bypass problems of impaired glucose access to the brain during aging. Hence, it may be time to consider whether the main omega-3 fatty acids have distinct but complementary roles in brain function.
Freemantle
Erika
E
Research Centre on Aging, 1036 Belvedere Street South, Université de Sherbrooke, Sherbrooke, Qué., Canada J1H 4C4.
Vandal
Milène
M
Tremblay-Mercier
Jennifer
J
Tremblay
Sébastien
S
Blachère
Jean-Christophe
JC
Bégin
Michel E
ME
Brenna
J Thomas
JT
Windust
Anthony
A
Cunnane
Stephen C
SC
D000375:Aging / Q000502:physiology*; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D050260:Carbohydrate Metabolism / Q000187:drug effects / Q000502:physiology; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D008954:Models, Biological
D015525:Fatty Acids, Omega-3